Prothena’s research and development pipeline includes three lead therapeutic antibody programs that we are advancing aggressively: NEOD001 for the treatment of AL and AA Amyloidosis; PRX002 for the treatment of Parkinson’s disease; and PRX003 for the potential treatment of inflammatory disease and metastatic cancers. NEOD001 is in Phase 1 development, and in both 2014 and 2015, we anticipate moving one or more of our other product candidates into the clinic.
Prothena’s pipeline includes several discovery-stage programs studying antibodies that may offer potential treatments for Alzheimer’s disease and Type 2 Diabetes. The Company continues to generate additional novel antibodies against other targets involved in protein misfolding and cell adhesion.
Prothena employs three distinct strategies to ensure we are allocating our resources towards the appropriate antibody and target disease, potentially increasing the likelihood each compound will complete Phase 3 development successfully. We leverage our insight into the pathology of diseases involving protein misfolding and cell adhesion to employ biomarker endpoints in order to detect signals of clinical efficacy early in the clinical development process. We collaborate with scientists who are recognized as experts in our disease areas of interest to test and characterize our potential therapeutic antibody candidates. We seek feedback and guidance on our programs from leading clinical experts. We believe these strategies give us the opportunity to make the most educated decisions about our compounds throughout the development process.